+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 85Years
All Genders
ID06800963

Phase 12 Study of Intravesical Recombinant Mycobacterium BCG for Adults with Non-Muscle Invasive Bladder Cancer Eligible for Tice BCG Treatment

Led by ImmunityBio, Inc. · Updated on 2026-03-27

40

Participants Needed

9

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating intravesical Recombinant Mycobacterium Bacillus Calmette-Gue9rin rMBCG in adults with non-muscle invasive bladder cancer NMIBC who have not previously received BCG treatment. This phase 12, open-label, multicenter study focuses on participants with confirmed carcinoma in situ CIS or primaryrecurrent stage Ta andor T1 papillary tumors following transurethral resection. The study aims to assess the safety and effects of this biological treatment in this patient group. Participants will receive an induction course of rMBCG administered directly into the bladder via a urinary catheter. The dose consists of 1 vial containing 19.2e8 colony-forming units CFU delivered intravesically. This single-arm study monitors participants through the treatment phase to evaluate safety outcomes over approximately seven months. During the study, participants will be closely monitored for safety by tracking the incidence and severity of adverse events. Evaluations include clinical assessments and laboratory tests at regular intervals. Participants must provide written consent and agree to comply with study procedures and follow-up evaluations. The total duration includes the treatment period and safety observation lasting about seven months.

CONDITIONS

Brief Title

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Research Team

J

Jayson Garmizo

N

Natalie Fernandez

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here